
jan pm et
summari maker radiotherapi cancer system also suppli x-ray tube flat-panel digit
subsystem imag medic scientif industri applic
price-to-earnings oper ep
past perform indic futur perform reli upon
analysi prepar equiti analyst
pm stock trade
target price recent
chang highlight
section stock report updat
invest rationale/risk section
stock report updat shortli
latest news stori marketscop
see
et cfra keep hold
system rais
target slightli
peer fy sep ep estim
earn benefit
new tax legisl forecast effect
tax rate fy
dec-q ep vs ahead
estim sale rose oncolog
sale particl therapi
book two new proton order
oncolog order rose encourag
 rsquo solid book oncolog
believ grow faster
market averag radiat therapi jeffrey
risk assess reflect varian offer
technolog advanc product
oncolog equip industri oper
competit industri character technolog
innov new product entrant addit
although radiat therapi continu integr
compon global cancer treatment protocol
continu develop drug-bas oncolog
treatment repres substanti threat
affect capit expenditur decis varian
fiscal year end sep ep estim base cfra
oper earn histor earn report
stk
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview varian one largest manufactur oncolog diagnost product x-ray
tube imag subsystem compani focus primarili captur share global
oncolog radiat therapi market cancer rate expect increas calendar
market profil driven age global popul improv diagnost method number
newli diagnos cancer case continu increas number new cancer case diagnos annual
project increas million new case million
accord intern agenc research cancer world organ
radiat therapi commonli use treatment cancer alon combin surgeri
chemotherapi common type radiotherapi use x-ray deliv extern beam
administ use linear acceler addit extern radiat radioact seed wire ribbon
sometim insert tumor bodi caviti brachytherapi modal
requir radiat pass healthi tissu
varian oncolog system group design market servic hardwar softwar product
cancer radiat treatment includ linear acceler treatment simul verif product
well softwar system plan cancer treatment manag inform imag
radiat oncolog product focu enabl new therapi deliv high dose radiat
tumor reduc risk surround tissu three-dimension conform radiat therapi
driver softwar treatment deliveri devic linear acceler design allow
clinician determin deliv clinic optim plan radiat patient imrt use
treat head neck breast prostat pancreat lung liver gynecolog central nervou system
cancer rapidarc radiotherapi technolog allow clinician program varian linear acceler
deliv precis form imrt faster possibl convent imrt also develop
image-guid radiat therapi igrt improv radiat therapi precis use technolog
compens tumor chang movement treatment
varian sell x-ray product includ x-ray gener tube use four primari medic x-ray imag
applic ct scanner radiographic/fluoroscop special procedur mammographi offer
line industri x-ray tube consist analyt x-ray tube use x-ray fluoresc
diffract well tube non-destruct imag gaug airport baggag inspect
system compani also design manufactur flat panel detector incorpor
next-gener medic diagnost industri imag system
varian third report segment consist secur inspect product sip gintzon
technolog center gtc varian particl therapi vpt busi unit sip design manufactur
sell servic x-ray acceler imag process softwar imag detect product
cargo screen port border non-destruct examin product gener sold
origin equip manufactur incorpor product inspect system
gtc varian research facil develop technolog enhanc current busi may lead
new busi opportun includ next-gener digit x-ray imag technolog volumetr
function imag improv x-ray sourc technolog secur cargo screen applic
compani also develop technolog product may improv diseas manag
precis target radiat therapi
vpt busi develop design manufactur sell servic proton therapi system cancer
treatment scientif research oppos standard proton radiotherapi beam pass
way patient bodi proton therapi beam design stop distribut
radiat dose site tumor therapi thought especi use pediatr case
larg tumor ocular tumor tumor adjac sensit healthi tissu
competit landscap market radiat therapi equip softwar character
rapidli evolv technolog intens competit price pressur view new
competitor potenti disrupt overal market think global market radiat
therapi equip domin varian elekta ab accuray incorpor
innov offic
senior vice-president financ
senior vice presid
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
overvalu
neutral sinc januari technic indic
neutral
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
fundament outlook health care
equip sub-industri next month
neutral continu view mani product
categori histor recession-resist
expect continu grow albeit
slowli growth procedur rate
slow area normal view
non-elect cardiac rhythm
manag intervent cardiolog
orthoped recent howev equip
maker think certain procedur rate may
stabil start recov
medic devic tax requir
healthcar reform law went effect
januari temporarili
suspend
elect donald trump republican
retain control congress believ
gop abil substanti alter
afford act includ potenti
elimin variou health care sector fee
tax although gop replac
remain uncertain believ
potenti fewer insur patient
neg impact equip sub-industri
fewer insur patient would like lead
fewer procedur anticip
hospit largest buyer
medic equip would also advers
impact could pressur
expect revenu rise constant
currenc mid- upper-singl digit pace
aid new product expans emerg
market case acquisit
still expect extend replac cycl
 hospit area price
demand certain product categori
unfavor foreign exchang continu
hospit becom cautiou regard
base index
five-year market price perform jan
capit budget amid shift
procedur inpati outpati
includ increas global demand
qualiti health care age popul
rise outlay lead steadi flow
new diagnost therapeut product
 health equip
sub-index increas vs rise
 composit index follow
rise health equip
index vs declin
composit index year date
juli health
equip index rose vs rise
 composit index
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
march inc announc elect jo
baselga jean-luc butel director compani effect march
effect may dr baselga appoint nomin
corpor govern committe ethic complianc committe mr
butel appoint audit committe compens
et cfra keep hold opinion share varian medic
system inc keep target in-lin
peer fy sep ep estim lower
mar-q ep vs
estim sale rose oncolog system particl
therapi gross order oncolog rose book new proton
order new single-room probeam compact system delray florida
also select provid singl room probeam compact proton system
thailand expect book jun-q overal backlog rose
announc jo baselga physician-in-chief
memori sloan ketter cancer center msk professor medicin
weill cornel medic colleg jean-luc butel senior advis
mckinsey healthcar practic appoint varian board
director effect march serv re-elect
successor elect next annual meet stockhold dr
baselga serv physician-in-chief msk professor medicin weill
cornel medic colleg sinc prior msk dr baselga chief
divis hematolog /oncolog associ director
massachusett gener hospit cancer center professor medicin
harvard medic school butel serv senior advis
mckinsey healthcar practic sinc butel serv
corpor vice presid presid baxter
analyst research note compani news
et cfra keep hold opinion share varian medic
system rais target slightli
peer fy sep ep estim earn
benefit new tax legisl forecast effect tax rate
fy dec-q ep vs ahead
estim sale rose oncolog sale particl therapi
book two new proton order oncolog order rose
encourag var solid book oncolog believ
grow faster market averag radiat therapi jeffrey
system announc halcyon system receiv
fda approv taiwan compani also announc sign
understand mou technolog co subsidiari
major chines health care provid explor strateg partnership expand
cancer care china think announc encourag
continu growth asia continu believ halcyon oversea expans
benefit top line growth remain cautiou address market
expans materi earn growth near term /danni
et cfra keep hold opinion share varian medic
system sept-q ep vs
estim lower fy sept ep sale fell
oncolog system sale rose proton therapi sale fell expect
proton therapi sale remain volatil next year
increas scale current clinic oper site
room countri howev encourag gross order rate
includ order china india fy new
order across countri within oncolog sept-q order
announc name terilyn juarez monro chief
ms replac wendi scott retir serv
role varian year ms serv past two year
chief peopl cultur offic svp hr acxiom \nprior acxiom
ms spent year held sever hr manag role
includ chief divers offic director talent engag
announc name michael bruff vice
presid investor relat effect august mr bruff replac
spencer sia retir june mr bruff serv year
domest intern role recent senior vice presid
north america sale strategi plan previous serv senior
vice presid cfo dell sasia pacif japan commerci busi
vice presid greater china commerci busi also held execut
leadership role financi plan analysi intern audit
enterpris solut group financ addit mr bruff vice presid
global servic account financ at\nca inc held varieti
financ account role deloitt
system rais target price
in-lin peer fy sep ep estim jul-q ep
vs ahead estim sale rose oncolog
gross order robust demand asia particl therapi sale
robust book three proton order quarter includ
multi-room facil georgia proton therapi center backlog rose
encourag recent book still see signific
variabl quarter-to-quart particularli particl therapi unit
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd
repres total revenu estim
fiscal year analyst estim earn per
share grow usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut standard
 poor malaysia sdn bhd cfra malaysia certain research distribut
cfra uk limit cfra uk cfra uk cfra malaysia wholly-own
subsidiari cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
